Asymmetric [2+2] Cycloaddition Reaction between α,β-Unsaturated Acid Derivatives and Alkynyl or Alkenyl Sulfides Catalyzed by a Chiral Titanium Reagent
作者:Yujiro Hayashi、Koichi Narasaka
DOI:10.1246/cl.1990.1295
日期:1990.8
Asymmetric [2+2] cycloaddition reaction between 3-(acryloyl)-1,3-oxazolidin-2-one derivatives and alkynyl or alkenyl sulfides proceeds by the use of a chiral titanium reagent to give the corresponding cyclobutene or cyclobutane derivatives in high enantioselectivity.
Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
申请人:——
公开号:US20040043998A1
公开(公告)日:2004-03-04
The present invention provides a preventive or therapeutic medicine for diabetes containing as an active ingredient a fused-heterocyclic compound of the formula (I′) or its salt:
1
[wherein G is CN, NO
2
, CO
2
R
4
, CHO, SO
2
NR
a
R
b
or CONR
a
R
b
; R
1
is a halogen atom, a —O—R
5
group or a —S—R
5
group; R
2
is a halogen atom, a O—R
5
group (wherein R
5
is as defined above) or an amino group which may be substituted; and each of R
8
and R
10
which are independent of each other, is a hydrogen atom, a halogen atom or an alkyl group].
PREVENTIVE OR THERAPEUTIC MEDICINES FOR DIABETES CONTAINING FUSED-HETEROCYCLE COMPOUNDS OR THEIR SALTS
申请人:ISHIHARA SANGYO KAISHA, LTD.
公开号:EP1334973A1
公开(公告)日:2003-08-13
The present invention provides a preventive or therapeutic medicine for diabetes containing as an active ingredient a fused-heterocyclic compound of the formula (I') or its salt:
[wherein G is CN, NO2, CO2R4, CHO, SO2NRaRb or CONRaRb; R1 is a halogen atom, a -O-R5 group or a -S-R5 group; R2 is a halogen atom, a -O-R5 group (wherein R5 is as defined above) or an amino group which may be substituted; and each of R8 and R10 which are independent of each other, is a hydrogen atom, a halogen atom or an alkyl group].